New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma.
New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma. Blood Adv. 2026 Jan 13; 10(1):217-227.
PMID: 40811818
Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis.
Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis. Blood Adv. 2025 Nov 11; 9(21):5654-5662.
PMID: 40763269
A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL.
A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL. Blood Adv. 2025 Nov 11; 9(21):5665-5675.
PMID: 40720747
Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study.
Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study. Blood Adv. 2025 Aug 12; 9(15):3694-3705.
PMID: 40305658
Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: A CIBMTR Analysis.
Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: A CIBMTR Analysis. Transplant Cell Ther. 2025 Dec; 31(12):1000.e1-1000.e11.
PMID: 40754223
Cilta-cel salvages ide-cel failure in relapsed multiple myeloma by driving distinct immune responses.
Cilta-cel salvages ide-cel failure in relapsed multiple myeloma by driving distinct immune responses. medRxiv. 2025 Jul 11.
PMID: 40672475
CAR-T cell therapy in older adults with relapsed/refractory LBCL: benefits and challenges.
CAR-T cell therapy in older adults with relapsed/refractory LBCL: benefits and challenges. J Immunother Cancer. 2025 Jun 05; 13(6).
PMID: 40480655
Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma.
Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma. Blood. 2025 Jun 05; 145(23):2762-2767.
PMID: 39938007
Low-Strength Type I Interferon Signaling Promotes CAR T-Cell Treatment Efficacy.
Low-Strength Type I Interferon Signaling Promotes CAR T-Cell Treatment Efficacy. bioRxiv. 2025 May 20.
PMID: 40463198
Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study.
Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study. Blood. 2025 May 15; 145(20):2303-2311.
PMID: 39938019